Search peptides, terms, sources/
Research source · 2020

Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials

About this source

Kind
Research
Design
Human clinical trial
Population
10 people with POMC deficiency and 11 with LEPR deficiency, 10 hospitals
Sample size
21
Primary or secondary
primary
Peer review
peer reviewed
Retraction status
None known
Date checked
14 November 2026

Limitations

Two small single-arm, open-label trials with no control group, in ultra-rare conditions. Registrations NCT02896192 and NCT03287960. Verified via Europe PMC on 14 November 2026 (title subtitle taken from the trial design as reported there).

Cited in

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.